These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 11489221

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
    Schuchter K, Hafner E, Stangl G, Ogris E, Philipp K.
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B, Slack A, Wathen NC.
    Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K, Nicolaides KH.
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [Abstract] [Full Text] [Related]

  • 10. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [Abstract] [Full Text] [Related]

  • 11. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome.
    Lam YH, Lee CP, Sin SY, Tang R, Wong HS, Wong SF, Fong DY, Tang MH, Woo HH.
    Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586
    [Abstract] [Full Text] [Related]

  • 12. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E, van Lith JM, Mol BW, Bleker OP, Bilardo CM.
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [Abstract] [Full Text] [Related]

  • 13. Prospective assessment of the Hong Kong Hospital Authority universal Down syndrome screening programme.
    Sahota DS, Leung WC, Chan WP, To WW, Lau ET, Leung TY.
    Hong Kong Med J; 2013 Apr; 19(2):101-8. PubMed ID: 23535668
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Down syndrome screening in France: the worst consensus].
    Rozenberg P, Bussières L, Senat MV.
    J Gynecol Obstet Biol Reprod (Paris); 2007 Apr; 36(2):95-103. PubMed ID: 17289296
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.